Company intelligence / Profile preview

Dalian Wista Pharma

Dalian, Liaoning, China

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Dalian Wista Pharma is the primary research, development, and manufacturing arm of TauRx Pharmaceuticals. The company is focused on the development of tau aggregation inhibitors for the treatment of neurodegenerative diseases. Its lead candidate, hydromethylthionine mesylate (HMTM), has completed Phase 3 clinical trials (LUCIDITY), demonstrating significant reduction in cognitive decline and brain atrophy in patients with Alzheimer's disease. The company is currently preparing for global regulatory submissions.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

TauRx PharmaceuticalsUniversity of Aberdeen

Beyond the preview

Go deeper on Dalian Wista Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dalian Wista Pharma.

Explore the full profile